Infex strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex webinar - broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex CSO invited to speak at GARDP REVIVE Webinar
On 27th June, Dr Victoria Savage, Chief Scientific Officer for Infex…
Infex to present webinar on broader pipeline and growth strategy
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Webinar on Infex's Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…